Trial Profile

A Study to Evaluate the Efficacy and Safety of Tasimelteon in Treating Sleep Disturbances in Individuals With Autism Spectrum Disorder

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 26 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tasimelteon (Primary)
Indications Autistic disorder
Focus Registrational; Therapeutic Use
Sponsors Vanda Pharmaceuticals

Most Recent Events

19 Mar 2024 Planned End Date changed from 1 Jul 2023 to 1 Jul 2025.
19 Mar 2024 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2025.
29 Apr 2022 Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com